Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome
Pilot Study of Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female
- Age 12-21 years
- 45,XO karyotype in >50% of cells tested with a diagnosis of Turner syndrome (TS)
- Tanner stage 2-5 for breast development
Exclusion Criteria:
- Growth hormone treatment within the past 3 months
- Diagnosis of type 1 or type 2 diabetes
- Untreated hypertension with blood pressure > 99%ile for sex, age and height or >140/90
- Weight > 300 lbs
- Height < 54"
- Aortic sinus of Valsalva or ascending aorta z-score > 2
- Other cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures, including vigorous exercise
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Adolescents
Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
|
No intervention
|
|
Parents
One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
|
No intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak oxygen consumption
Time Frame: Baseline
|
Peak oxygen consumption (VO2 peak) with a standard graded exercise (bicycle) test
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life Survey
Time Frame: Baseline
|
Self and parent reported quality of life
|
Baseline
|
|
Percent body fat
Time Frame: Baseline
|
Body composition by dual-energy x-ray absorptiometry
|
Baseline
|
|
Insulin resistance (IR)
Time Frame: Baseline
|
Fasting insulin and glucose used to calculate homeostatic model assessment (HOMA)
|
Baseline
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Qualitative structured interview
Time Frame: Baseline
|
Attitudes surrounding physical activity participation
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shanlee Davis, MD, MS, University of Colroado
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Endocrine System Diseases
- Disease
- Gonadal Disorders
- Disorders of Sex Development
- Urogenital Abnormalities
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Chromosome Disorders
- Sex Chromosome Disorders
- Sex Chromosome Disorders of Sex Development
- Syndrome
- Turner Syndrome
- Gonadal Dysgenesis
Other Study ID Numbers
Other Study ID Numbers
- 17-0142
- UL1TR001082 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Turner Syndrome
-
NCT03274973Terminated
-
NCT00699855CompletedGrowth Hormon Deficiency | Turner Syndrome in Pre-pubertal Children
-
NCT05330325Active, not recruitingSGA, Turner Syndrome, Noonan Syndrome, ISS
-
NCT07304193Enrolling by invitationSex Chromosome Disorders
-
NCT00870220TerminatedTurner's Syndrome
-
NCT00004275Completed
-
NCT01813630CompletedTurner's Syndrome
-
NCT03441347CompletedParsonage Turner Syndrome | Neuralgic Amyotrophy | Neuralgic Amyotrophy, Hereditary | Brachial Neuritis
-
NCT02226315TerminatedDown Syndrome | Turner Syndrome | Edwards Syndrome | Patau Syndrome
-
NCT06740656Not yet recruitingMyositis | Neuropathy | Parsonage Turner Syndrome | Myasthaenia Gravis | Guillain Barré Syndrome
Clinical Trials on No intervention
-
NCT06980844Not yet recruitingInterstitial Lung Disease
-
NCT02746445Completed
-
NCT05345054CompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social Behavior
-
NCT01923415CompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, Discoid
-
NCT06134739RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | Ablation
-
NCT03305484CompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein Staining
-
NCT06686342RecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in Vitro
-
NCT03385811UnknownIntention to Stay, Turnover Behavior